View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 17, 2011

Chimerix Initiates Patient Dosing in AdV HALT Study

Chimerix has begun patient dosing in a randomised, placebo-controlled study of CMX001, which is being developed as a potential broad spectrum, oral antiviral product for the treatment or prevention of double-stranded DNA viral diseases. The Phase II AdV HALT Trial is intended to evalua

By cms admin

Chimerix has begun patient dosing in a randomised, placebo-controlled study of CMX001, which is being developed as a potential broad spectrum, oral antiviral product for the treatment or prevention of double-stranded DNA viral diseases.

The Phase II AdV HALT Trial is intended to evaluate the safety and efficacy of CMX001 to prevent immunocompromised paediatric and adult patients with asymptomatic adenovirus infection from developing disease.

The randomised, placebo-controlled, multi-site AdV HALT trial, which will be carried out across 30 centres, will enrol 48 paediatric and adult patients who have undergone haematopoietic stem cell transplantation.

The US Food and Drug Administration has granted CMX001 fast-track designation status for the development programme for this indication.

The primary endpoint will be ‘treatment failure’, consisting of progression to AdV disease or increasing AdV viraemia.

Secondary endpoints include safety and tolerability of CMX001, as well as other measurements.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology